Supply chain management in the pharmaceutical industry in Poland 2008

Description

The report comprises the complete economic analysis of pharmaceutical sector in Poland as well as recent data on healthcare sector in the region and contains forecast projections for 2009-2011.

The value data are presented for the total market, pharmacy and hospital segment, Rx, foreign and domestic drugs, generic and innovative medicines, and main ATC categories together with forecasts.

The report offers insights into ongoing trends, taking a closer look at areas of growth and decline. Factors that influence the market, from epidemiology to consumer behaviour, are studied and presented for your thorough understanding of the market. Economic data, such as employment and cost-revenue analysis of the pharmaceutical sector, are also covered.

As in other years, this year’s edition of our pharmaceutical and healthcare market report delivers a comprehensive overview on the Polish pharmaceutical market, with information on current and anticipated trends, market value and events, as well as forecasts for market growth, for the entire market and by the individual drug categories. Additionally, the most recent regulatory changes and their market impact has been reviewed, including the amendments to Pharmaceutical Act and reimbursement lists.The market consequences of the upcoming amendments has been estimated.

The pharmaceutical market in Poland has developed dynamically in the past five years, weathering difficult market conditions. As demonstrated by the results of our study, the current economic situation linked to the global economic crisis has not affected the positive performance of the pharmaceutical sector, nor has it had an adverse effect on the optimistic mood which prevails among pharmaceutical companies in Poland. In 2008 the pharmaceutical market in Poland was worth PLN 24.1bn, which represented 11.5% growth in comparison with 2007. At present, it is among the areas of the Polish economy boasting the strongest future growth prospects. According to our forecasts, in 2009-2011 the CAGR (Compound Annual Growth Rate) will be 7.4%, whereas pharmaceutical companies expect it to reach approx. 6%. In terms of sales value, the Polish pharmaceutical market is the sixth largest in the European Union, while in terms of the rate of sales growth (as expressed in euro), it was the second fastest growing market in the EU in 2007-2008.

Report overview

The report opens with an introduction presenting its objectives and target readership. It then introduces research methods employed in the study and provides a summary and a presentation of its most important conclusions. What follows is a thorough analysis of the pharmaceutical and healthcare market in Poland, with special attention given to the following aspects:

• detailed information on legal environment together with most important changes in the “minor” and “major” amendments to the Pharmaceutical Act, analysis of changes is Act on Healthcare Services Financed from Public Funds
• analysis of latest novelisations of reimbursement lists and their impact on the market
• profiles of largest players active on pharma market
• strategic key data
• data needed for market entry
• description of epidemiologic and demographic trends
• economic trends analysis
• consumer behaviour in Poland analysis

TABLE OF CONTENT

Report methodology 15
Executive summary 19
Overview of the pharmaceutical market in Poland 25
Key events and trends in 2008-2009 25
Key events and trends anticipated for 2009-2010 27
Size of Polish pharmaceutical market 29
Pharmaceutical market in 2002-2011 29
Pharmacy sales in 2002-2008 29
Development forecasts for pharmacy sales in 2009-2011 30
Number of packages sold in 2002-2008 32
Domestic and foreign pharmaceuticals 32
Original and generic pharmaceuticals 37
Overview of the hospital drug market in Poland 41
Value of hospital market in 2000-2010 41
Financial standing of public healthcare facilities 42
Drug therapy programmes 44
Spending on chemotherapy 46
Drug prices 47
Average drug prices on the pharmacy market 47
Average drug prices on the hospital market 48
Average prices of domestic and foreign pharmaceuticals 48
Prices on aggregate pharmacy market 48
Prices of Rx drugs 49
Prices of refunded drugs 49
Average prices of innovative and generic drugs 50
Average prices in therapeutic groups 50
Analysis of ATC groups, showcasing Rx drugs 50
Analysis of ATC subgroups, showcasing Rx drugs 53
Average prices of concern drugs 58
Prices on the pharmacy market 58
Rx drug prices 60
Drug prices in Poland and in other European countries 61
Drug reimbursement in Poland 62
NFZ expenditure on drug reimbursement 62
Share of reimbursement in pharmacy trade 62
Structure of drug reimbursement 63
Reimbursement structure by reimbursement type 63
Reimbursement structure by therapeutic groups 64
eimbursement structure by domestic and foreign drugs 65
Reimbursement structure by active substances 66
Reimbursement structure by product 66
Reimbursement structure by manufacturer 67
Legislative changes and their impact on the drug reimbursement market 68
New reimbursement lists 68
Amendment to Pharmaceutical Law 69
Foreign trade 70
Export 70
Import 73
Pharmacy market by therapeutic groups 77
Market value shares of ATC groups 77
Pharmacy market 77
Rx market 78
Market volume shares of ATC groups 80
Pharmacy market 80
Rx market 81
Alimentary tract and metabolism 82
Market size and forecasts 82
Key categories of drugs used in alimentary tract and metabolic diseases 84
Drugs used in diabetes 85
Vitamins and mineral supplements 86
Antacids, antiflatulents and anti-ulcerants 86
Antidiarrhoeals, oral electrolyte replacers and intenstinal anti-inflammatories 86
Antiobesity preparations 87
Best selling preparations 87
Cardiovascular system 88
Market size and forecasts 88
Key categories of drugs used in cardiovascular diseases 90
Agents acting on the renin-angiotensin system 91
ipid regulators 91
Beta blocking agents 92
Antihypertensives 92
Best selling preparations 93
Central nervous system 93
Market size and forecasts 93
Key categories of drugs used in central nervous system diseases 95
Analgesics 96
Psycholeptics 96
Psychoanaleptics 97
Best selling preparations 98
Respiratory system 98
Market size and forecasts 98
Key categories of drugs used in respiratory
system diseases 100
Anti-asthma and COPD products 101
Cough and cold preparations 102
Systemic antihistamines 102
Nasal preparations 102
Best selling preparations 104
Anti-infectives 104
Market size and forecasts 104
Key categories of anti-infectives 106
Systemic antibacterials 106
Vaccines 107
Best selling preparations 107
Musculo-skeletal system 108
Market size and forecasts 108
Key categories of drugs used in musculo-skeletal diseases 110
Anti-inflammatory and anti-rheumatic products 111
Topical anti-rheumatics 112
Drugs for disorders of the musculo-skeletal system 112
Best selling preparations 113
Genito-urinary system 113
Market size and forecasts 113
Key categories of drugs affecting genito-urinary
system 115
Sex hormones and products with similar desired effects, systemic use only 116
Urologicals 116
Best selling preparations 116
Dermatologicals 117
Market size and forecasts 117
Key categories of dermatologicals 119
Topical corticosteroids 120
Dermatological antifungals 120
Best selling preparations 121
Blood and blood forming organs 121
Market size and forecasts 121
Key categories of drugs used in diseases of the blood and blood forming organs 123
Antithrombotic agents 124
Anti-anaemic preparations 124
Best selling preparations 125
Antineoplastic and immunomodulating agents 125
Market size and forecasts 125
Key categories of antineoplastic and immunomodulating agents 127
Cytostatic hormone therapy 128
Immunostimulating agents 128
Immunosuppressants 128
Best selling preparations 129
Other ATC groups 129
Sensory organs 129
Systemic hormonal preparations 131
Parasitology 134
Various 136
Pharmaceutical companies in Poland 139
Number and classification of pharmaceutical manufacturers in Poland 139
Manufacturers of pharmaceutical substances 140
Drug manufacturers 140
Economic analysis of Polish pharmaceutical sector 141
Output of selected pharmaceutical products 141
Revenues 142
Profit 144
Operating expenses 145
Employment 146
Staffing levels 146
Labour productivity 147
Average remuneration 147
Investments in the Polish pharmaceutical sector in 2006 148
Investment number 148
Investment value 148
Largest foreign investments in Polish pharmaceutical industry 2007-2008 150
Expenditure on intangible fixed assets 151
Top drug makers in Poland 152
Top players on pharmacy market 152
Top players on the Rx market 157
Profiles of key players 163
Demographic trends 187
Population 187
Natural population growth 188
Ageing of society 189
Life expectancy 191
Gender structure 193
Degree of urbanisation 193
Epidemiological trends 195
The main health problems of Poles 195
Main causes of death 197
Key statistics 197
Poland compared with other European countries 198
Epidemiology of selected diseases in Polish society 199
Cardiovascular system diseases 199
Neoplasms 201
Diseases of the central nervous system 206
Respiratory system diseases 208
Diseases of the alimentary tract and metabolism 209
Consumer behaviour 211
Health assessment 211
What do Poles do to be healthy? 212
Sources of information about health and illnesses 213
Poles’ opinion about generic drugs 214
Poles’ opinions about innovative drugs 217
Factors influencing the purchase of OTC drugs 218
Frequency of OTC drug purchases 220
Most popular OTC drugs 220
Place of purchase of OTC drugs 221
Drug use in illness 223
Macroeconomic trends 225
GDP growth 225
Inflation 226
Unemployment 226
Wages 227
Regulatory environment 229
Regulations and institutions governing the pharmaceutical market in Poland 229
Key changes introduced by the “large amendment” to the Pharmaceutical Law 230
Key changes introduced by the amended
Healthcare Act 230
Anti-corruption provisions 230
Changes in reimbursement process 231
Greater control over the NFZ 232
Ordinance on Drug Advertising 232
Visits of medical representatives at public healthcare centres 232
Simultaneous advertising of several products 232
Risk warnings 233
Ban on audiovisual advertising in pharmacies 233
Compliance with Medicinal Product Characteristics 233
Transition provisions 233
Key amendments introduced by the “minor amendment” to the Pharmaceutical Law 233
Fixed prices and margins for reimbursed drugs 234
Anti-concentration regulations 235
Ban on advertising pharmacies 235
Changes in monitoring adverse reactions 235
Other regulations 236
Harmonisation of registration documentation 236
URPL Act 237
Distribution 239
Key events and trends on the distribution market in 2007-2009 239
Trends expected on the distribution market in 2009-2011 241
Key players on the drug distribution market 242
Pharmaceutical wholesalers 243
Wholesalers in Poland: number and business profiles 243
The largest players on the Polish wholesale market 245
Pharmacy distribution 254
Pharmacy count 254
Financial standing of Polish pharmacies 255
Pharmacy chains 256
Internet pharmacies 258
Healthcare market in Poland 261
Healthcare system in Poland 261
Sources of financing of the public healthcare system 262
Healthcare financing 262
Healthcare costs 265
Market of private medical services in Poland 267
Other data on health care in Poland 267

List of graphs 275
List of tables 285
About PMR 289
About PharmaExpert 291

By ordering a "single user licence" the client is purchasing the right to use the publication on one computer workstation only. Any copying, distribution or dissemination of the electronic publication via a computer network (in part or in whole) is strictly prohibited. Delivered by e-mail in PDF format.

By ordering a "5-user licence" the client is purchasing a licence authorising the copying, distribution and dissemination of the electronic publication via a computer network (in part or in whole) among a maximum of 5 people within the company indicated on the order form (including all company subsidiaries in a single country location). Delivered by e-mail in PDF format.

By ordering a "company licence" the client is purchasing a licence authorising the unrestricted copying, distribution and dissemination of the electronic publication (in part or in whole) via a computer network solely within the company indicated on the order form (including all company subsidiaries in a single country location). CD delivered by courier. CD version contains PDF version of the report plus an extra file with all the graphs and tables in a copiable format easy to use in your own analyses, presentations, etc.

By ordering a "global licence" the client is purchasing a licence authorising the unrestricted copying, distribution and dissemination of the electronic publication (in part or in whole) via a computer network solely within the organisation indicated on the order form, regardless of country location. CD delivered by courier. CD version contains PDF version of the report plus an extra file with all the graphs and tables in a copiable format easy to use in your own analyses, presentations, etc.